These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26396192)

  • 1. Natural Polymorphisms and Oligomerization of Human APOBEC3H Contribute to Single-stranded DNA Scanning Ability.
    Feng Y; Love RP; Ara A; Baig TT; Adolph MB; Chelico L
    J Biol Chem; 2015 Nov; 290(45):27188-27203. PubMed ID: 26396192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity.
    Refsland EW; Hultquist JF; Luengas EM; Ikeda T; Shaban NM; Law EK; Brown WL; Reilly C; Emerman M; Harris RS
    PLoS Genet; 2014 Nov; 10(11):e1004761. PubMed ID: 25411794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA-Mediated Dimerization of the Human Deoxycytidine Deaminase APOBEC3H Influences Enzyme Activity and Interaction with Nucleic Acids.
    Feng Y; Wong L; Morse M; Rouzina I; Williams MC; Chelico L
    J Mol Biol; 2018 Dec; 430(24):4891-4907. PubMed ID: 30414963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
    Feng Y; Love RP; Chelico L
    J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of APOBEC3F in the Presence of the APOBEC3 Antagonist HIV-1 Vif Increases at the Expense of Co-Expressed APOBEC3H Haplotype I.
    Yousefi M; Annan Sudarsan AK; Gaba A; Chelico L
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus-1 infection.
    Gourraud PA; Karaouni A; Woo JM; Schmidt T; Oksenberg JR; Hecht FM; Liegler TJ; Barbour JD
    Hum Immunol; 2011 Mar; 72(3):207-12. PubMed ID: 21167246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity.
    Wang X; Abudu A; Son S; Dang Y; Venta PJ; Zheng YH
    J Virol; 2011 Apr; 85(7):3142-52. PubMed ID: 21270145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of RNA in HIV-1 Vif-Mediated Degradation of APOBEC3H.
    Wang J; Becker JT; Shi K; Lauer KV; Salamango DJ; Aihara H; Shaban NM; Harris RS
    J Mol Biol; 2019 Dec; 431(24):5019-5031. PubMed ID: 31628948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flexibility in Nucleic Acid Binding Is Central to APOBEC3H Antiviral Activity.
    Bohn JA; DaSilva J; Kharytonchyk S; Mercedes M; Vosters J; Telesnitsky A; Hatziioannou T; Smith JL
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence and structural determinants of human APOBEC3H deaminase and anti-HIV-1 activities.
    Mitra M; Singer D; Mano Y; Hritz J; Nam G; Gorelick RJ; Byeon IJ; Gronenborn AM; Iwatani Y; Levin JG
    Retrovirology; 2015 Jan; 12():3. PubMed ID: 25614027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 Vif adaptation to human APOBEC3H haplotypes.
    Ooms M; Brayton B; Letko M; Maio SM; Pilcher CD; Hecht FM; Barbour JD; Simon V
    Cell Host Microbe; 2013 Oct; 14(4):411-21. PubMed ID: 24139399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Structural Interface between HIV-1 Vif and Human APOBEC3H.
    Ooms M; Letko M; Simon V
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and mechanistic basis for APOBEC3H alternative splicing, retrovirus restriction, and counteraction by HIV-1 protease.
    Ebrahimi D; Richards CM; Carpenter MA; Wang J; Ikeda T; Becker JT; Cheng AZ; McCann JL; Shaban NM; Salamango DJ; Starrett GJ; Lingappa JR; Yong J; Brown WL; Harris RS
    Nat Commun; 2018 Oct; 9(1):4137. PubMed ID: 30297863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms.
    Ara A; Love RP; Chelico L
    PLoS Pathog; 2014 Mar; 10(3):e1004024. PubMed ID: 24651717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif.
    Ooms M; Letko M; Binka M; Simon V
    PLoS One; 2013; 8(2):e57744. PubMed ID: 23469063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism in human APOBEC3H affects a phenotype dominant for subcellular localization and antiviral activity.
    Li MM; Emerman M
    J Virol; 2011 Aug; 85(16):8197-207. PubMed ID: 21653666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The range of human APOBEC3H sensitivity to lentiviral Vif proteins.
    Li MM; Wu LI; Emerman M
    J Virol; 2010 Jan; 84(1):88-95. PubMed ID: 19828612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms of the cytidine deaminase APOBEC3F have different HIV-1 restriction efficiencies.
    Mohammadzadeh N; Follack TB; Love RP; Stewart K; Sanche S; Chelico L
    Virology; 2019 Jan; 527():21-31. PubMed ID: 30448640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.